Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 43(1): 22-28, Jan.-Feb. 2021. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1153276

RESUMO

Objective: Clinical and biological correlates of resilience in major depressive disorder are scarce. We aimed to investigate the effect of the Val66Met polymorphism in the BDNF gene on resilience scores in major depressive disorder patients and evaluate the polymorphism's moderation effect on resilience scores in response to cognitive therapy. Method: A total of 106 major depressive disorder patients were enrolled in this clinical randomized study. The Resilience Scale and the Hamilton Rating Scale for Depression were applied at baseline, post-treatment, and at six months of follow-up. Blood samples were obtained at baseline for molecular analysis. Results: The baseline resilience scores were higher in patients with the Met allele (114.6±17.6) than in those with the Val/Val genotype (104.04±21.05; p = 0.037). Cognitive therapy treatment increased resilience scores (p ≤ 0.001) and decreased depressive symptoms (p ≤ 0.001). In the mixed-effect model, the Val/Val genotype represented a decrease in resilience scores (t218 = -1.98; p = 0.048), and the Val66Met polymorphism interacted with sex to predict an increase in total resilience scores during cognitive treatment (t218 = 2.69; p = 0.008). Conclusion: Our results indicate that cognitive therapy intervention could improve resilience in follow-up, considering that gender and genetic susceptibility are predicted by the Val66Met polymorphism.


Assuntos
Humanos , Terapia Cognitivo-Comportamental , Transtorno Depressivo Maior/genética , Transtorno Depressivo Maior/terapia , Polimorfismo Genético , Fator Neurotrófico Derivado do Encéfalo/genética , Polimorfismo de Nucleotídeo Único , Genótipo
2.
Adv Rheumatol ; 61: 24, 2021. tab
Artigo em Inglês | LILACS-Express | LILACS | ID: biblio-1248668

RESUMO

Abstract Background: The Val66Met polymorphism of the brain-derived neurotrophic factor (BDNF) gene is a potential biomarker of vulnerability to pain. Thus, the present study aimed to investigate the association of this polymorphism with clinical and biopsychosocial factors in patients with chronic low back pain (CLBP). Methods: A total of 107 individuals with CLBP answered questionnaires that were validated and adapted for the Brazilian population, including the Brief Inventory of Pain, the Central Sensitization Inventory, the Roland Morris Disability Questionnaire, the Tampa Scale for Kinesiophobia, the Pain Catastrophizing Scale, the Survey of Pain Attitude-Brief, and the Hospital Anxiety and Depression Scale. All of the subjects were genotyped for the BDNF Val66Met polymorphism. Results: The sample showed moderate scores of disability, central sensitization, and kinesiophobia, in addition to mild anxiety, hopelessness, and ruminant thoughts. No significant association was observed between the Val66Met polymorphism and the variables analyzed. Besides, there was no relationship between the BDNF Val66Met polymorphism with CSI, catastrophization, or disabilities that were generated by CLBP. Conclusions: The results showed that the Val66Met polymorphism of the BDNF gene was not associated with clinical and biopsychosocial characteristics of CLBP in the sample studied.

3.
Artigo | IMSEAR | ID: sea-210657

RESUMO

Single nucleotide polymorphism of brain derived neurotropic factor gene, also known as Val66Met or rs6562, wasfound to be linked to obesity. However, reports on the link between this gene variant and obesity in Caucasian andAsian populations are inconsistent. A meta-analysis was, therefore, performed to determine the association betweenVal66Met polymorphism and the risk of obesity. Electronic databases, including Embase, CINAHL, and PubMed,were searched for relevant studies published before November 2018. Random effects model was used to calculatethe pooled estimate based on the heterogeneity test results. Data were obtained from 11 studies involving 13,153individuals with obesity and 18,689 non-obese individuals. The overall estimated odds ratio did not support theproposed association (OR 0.9, 95% CI 0.793–1.136). Stratified analysis, however, showed that Val/Val genotype isassociated with increased risk of obesity among adults (OR 1.135, 95% CI 1.001–1.286) but associated with a reducedrisk among adolescents (OR 0.61, 95% CI = 0.376, 0.984). The results highlight the role of confounding factors thatneed to be addressed when making inference

4.
Adv Rheumatol ; 60: 39, 2020. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1130786

RESUMO

Abstract Background: Fibromyalgia (FM) is a musculoskeletal chronic pain syndrome that impacts negatively patient's daily lives. Its pathogenesis is characterized by a complex relationship between biological and psychosocial factors not fully understood yet. Pain catastrophizing is associated with FM and is an important predictor of outcomes. This study aimed to answer two questions: (i) whether the allele and genotype frequencies of BDNF Val66Met (rs6265) polymorphism differs between FM patients and healthy controls (HC); and (ii) if the BDNF Val66Met polymorphism is a factor that predicts pain catastrophizing in FM. Methods: In a cross-sectional design, 108 FM patients and 108 HC were included. FM patients responded to the Brazilian Portuguese version of the Pain Catastrophizing Scale (BP-PCS) to assess pain catastrophizing, as well as other validated tools for anxiety (The State-Trait Anxiety Inventory - STAI), depression (Beck Depression Inventory II -BDI-II) and functional aspects (Fibromyalgia Impact Questionnaire - FIQ; Central Sensitization Inventory validated and adapted for Brazilian population - CSI-BP; Pittsburgh Sleep Quality Index - PSQI; and Resilience Scale). All subjects were genotyped for the BDNF Val66Met polymorphism. Results: Val allele was significantly more frequent in FM patients compared to the control group (p < 0.05). Also, FM patients with Val/Val genotype showed more pain catastrophizing thoughts, and this genotype was significantly associated with magnification and rumination dimensions of BP-PCS (p < 0.05). Furthermore, there were significant differences in levels of anxiety and symptoms of depression, years of education, and the functional situation between the FM and control groups. Conclusions: The findings show an association of BDNF Val66Met polymorphism with pain catastrophizing in FM, which opens new avenues to comprehend the interplay between molecular genetic characteristics and neuroplasticity mechanisms underpinning FM.(AU)


Assuntos
Humanos , Fibromialgia/fisiopatologia , Polimorfismo de Nucleotídeo Único , Catastrofização , Estudos Transversais , Resultado do Tratamento
5.
Journal of Clinical Neurology ; : 511-516, 2019.
Artigo em Inglês | WPRIM | ID: wpr-764365

RESUMO

BACKGROUND AND PURPOSE: Brain-derived neurotrophic factor (BDNF) is a neuronal growth factor that plays an essential role in the maintenance of the nervous system. We have evaluated the peripheral blood protein levels of BDNF and the valine-to-methionine substitution at codon 66 (Val66Met) single-nucleotide polymorphism (SNP) as potential biomarkers for the early recognition of chemotherapy-induced peripheral neuropathy (CIPN) in non-Hodgkin lymphoma and multiple myeloma patients. METHODS: CIPN was assessed in 45 patients at the diagnosis and during vincristine or bortezomib-based therapy using objective [reduced version of the Total Neuropathy Score (TNSr)] and subjective (FACT-GOG-NTx) tools. Depression was assessed using the Patient Health Questionnaire-9 (PHQ-9) questionnaire. BDNF protein levels and the Val66Met SNP were determined using ELISA and Sanger sequencing. RESULTS: The pretreatment BDNF protein level was inversely correlated with the maximum TNSr, FACT-GOG-NTx, and PHQ-9 scores in both genotypes. BDNF patients with the Val/Val genotype demonstrated significantly higher maximum FACT-GOG-NTx and PHQ-9 scores than those with the Val/Met and Met/Met genotypes (Met-BNDF carriers). Correlations between PHQ-9 and TNSr score were found only in Met-BDNF carriers, suggesting that peripheral neuropathy and depression coincide in Met-BDNF carriers. CONCLUSIONS: Determining the BDNF protein levels before initiating chemotherapy might be a useful tool for CIPN risk assessment and preemptive dose modification. The present data should be validated in larger studies that include other neurotoxic agents.


Assuntos
Humanos , Biomarcadores , Fator Neurotrófico Derivado do Encéfalo , Códon , Depressão , Diagnóstico , Tratamento Farmacológico , Ensaio de Imunoadsorção Enzimática , Genes vif , Genótipo , Linfoma , Linfoma não Hodgkin , Mieloma Múltiplo , Sistema Nervoso , Neurônios , Doenças do Sistema Nervoso Periférico , Medição de Risco , Vincristina
6.
Clinical Psychopharmacology and Neuroscience ; : 270-278, 2016.
Artigo em Inglês | WPRIM | ID: wpr-108196

RESUMO

OBJECTIVE: To explore associations of the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism with cognitive functioning and psychopathology in patients with schizophrenia. METHODS: We included 133 subjects meeting the DSM-IV criteria for schizophrenia who were in the post-acute stage of the disease. BDNF Val66Met genotypes were identified via polymerase chain reaction. The computerized neurocognitive function battery, Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Social and Occupational Functioning Scale (SOFAS), and the Subjective Well-being under Neuroleptic Treatment (SWN-K) were administered. Gender-stratified sub-analysis was also conducted to identify gender-specific patterns in the findings. RESULTS: In male patients, no significant difference in any measure by BDNF genotype was evident. In female patients, scores on the CDSS and total PANSS and all subscales were significantly higher in valine (Val) carriers. In addition, scores on the SOFAS and SWN-K were significantly lower in Val carriers. In terms of neurocognitive measures, female patients with the Val allele had significantly poorer reaction times and fewer correct responses on the Continuous Performance Test (CPT) and the Trail Making Test (Parts A and B). After adjustment of PANSS total scores and log-transformed CDSS scores, CPT outcomes were significantly poorer in female patients with than in those without the Val allele. CONCLUSION: Gender-specific associations of the Val allele with poor neurocognitive function and more severe psychopathology were evident. Further studies are required to explore the mechanisms of these differences and the potential utility of the BDNF genotype as a predictor of outcome in patients with schizophrenia.


Assuntos
Feminino , Humanos , Masculino , Alelos , Fator Neurotrófico Derivado do Encéfalo , Cognição , Depressão , Manual Diagnóstico e Estatístico de Transtornos Mentais , Genótipo , Reação em Cadeia da Polimerase , Polimorfismo Genético , Psicopatologia , Tempo de Reação , Esquizofrenia , Teste de Sequência Alfanumérica , Valina
7.
Psychiatry Investigation ; : 333-340, 2016.
Artigo em Inglês | WPRIM | ID: wpr-19525

RESUMO

OBJECTIVE: It has been known that mind-body training (MBT) can affect personality and behavior system as well as emotional well-being, but different effects of MBT on them has not been reported according to BDNF genetic polymorphism. METHODS: Healthy subjects consisted of 64 subjects and the MBT group who practiced meditation regularly consisted of 72 practitioners. Participants completed neuroticism-extraversion-openness (NEO) Five-Factor Inventory and Behavioral Activation System/Behavioral Inhibition System (BAS/BIS) scales. All subjects were genotyped for the BDNF Val66Met polymorphism. RESULTS: In the same genotypes of the BDNF Val/Val+Val/Met group, MBT group showed the increased Extraversion (p=0.033) and the increased Openness to Experience (p=0.004) compared to the control group. Also, in the same Met/Met carriers, MBT group exhibited the increase of Extraversion (p=0.008), the reduction of Neuroticism (p=0.002), and the increase of Openness to Experience (p=0.008) compared to the control group. In the same genotypes of the BDNF Val/Val+Val/Met group, MBT group showed the decreased BAS-Reward Responsiveness (p=0.016) and the decrease of BIS (p=0.004) compared to the control group. In the BDNF Met/Met group, MBT group increased BAS-Fun Seeking (p=0.045) and decreased BIS (p=0.013) compared to the control group. CONCLUSION: MBT would differently contribute to NEO personality and BAS/BIS according to BDNF genetic polymorphism, compensating for different vulnerable traits based on each genotype.


Assuntos
Fator Neurotrófico Derivado do Encéfalo , Extroversão Psicológica , Genótipo , Meditação , Polimorfismo Genético , Pesos e Medidas
8.
Psychiatry Investigation ; : 192-199, 2014.
Artigo em Inglês | WPRIM | ID: wpr-225627

RESUMO

OBJECTIVE: We investigated possible association between depressive disorders and BDNF Val66Met and 5-HTTLPR. Brain derived neurotrophic factor (BDNF) gene and serotonin transporter (SLC6A4) gene are promising candidate genes for depressive disorders. It has been suggested that BDNF promotes the survival and differentiation of serotonergic neurons and that serotonergic transmission exerts powerful control over BDNF gene expression. METHODS: Final analyses were performed on 186 patients with depressive disorders and 1032 controls. Val66Met polymorphism of BDNF gene and 5-HTTLPR polymorphism of serotonin transporter gene were genotyped and allele and genotypic associations on the diagnosis of depression and age at onset of depression were analyzed. RESULTS: The 5-HTTLPR was positively associated with depressive affected status in the total sample and in females (p=0.038 for allelewise, p=0.015 for genotype-wise associations), but, not in males. The BDNF Val66Met showed no association with depression. BDNF Val66Met and 5-HTTLPR alone were not associated with age at onset of depression. Additional analysis on the interaction between BDNF Val66Met and 5-HTTLPR found a significant association with age at onset of depression in the entire patient group. This association was also found in the female but not in the male patient group. None of the positive results survived Bonferroni correction for multiple testing. CONCLUSION: This result suggested that BDNF Val66Met and 5-HTTLPR may contribute to depressive disorders in a complex way and that the genetic effect could differ by gender. Further studies with large number of patients will be necessary.


Assuntos
Feminino , Humanos , Masculino , Alelos , Fator Neurotrófico Derivado do Encéfalo , Depressão , Transtorno Depressivo , Diagnóstico , Expressão Gênica , Polimorfismo Genético , Neurônios Serotoninérgicos , Proteínas da Membrana Plasmática de Transporte de Serotonina
9.
Psychiatry Investigation ; : 173-179, 2013.
Artigo em Inglês | WPRIM | ID: wpr-42590

RESUMO

OBJECTIVE: Genetic imaging is used to investigate the mechanism by which genetic variants influence brain structure. In a previous study, a structural change of the dorsolateral prefrontal cortex was associated with symptom modulation in post-traumatic stress disorder patients. This study examined the effect of a polymorphism in the gene encoding brain-derived neurotrophic factor (BDNF) on regional gray matter (GM) volumes and the correlations between the dorsolateral prefrontal GM volume and the stress level in healthy volunteers. METHODS: Sixty-one volunteers underwent genotyping for the BDNF Val66Met single nucleotide polymorphism (SNP) and completed the Stress Response Inventory (SRI). Magnetic resonance images were also acquired, and the effect of each subject's BDNF genotype and SRI subscore on his or her dorsolateral prefrontal GM volume was evaluated. RESULTS: The Val/Val homozygotes had significantly larger GM volumes in the prefrontal cortex and the precuneus, the uncus, and the superior temporal and occipital cortices than Met carriers. The Met homozygotes demonstrated a higher stress response in depression domain than Val/Val and Val/Met groups. A negative correlation between the middle frontal cortex GM volume and the SRI depression subscore was found. CONCLUSION: These findings indicate an interaction between genes and brain structure, and they suggest that differences in dorsolateral prefrontal GM volume related to the BDNF Val66Met SNP are associated with resilience to stressful life events, particularly in the dimension of emotion.


Assuntos
Humanos , Encéfalo , Fator Neurotrófico Derivado do Encéfalo , Depressão , Genótipo , Homozigoto , Imageamento por Ressonância Magnética , Espectroscopia de Ressonância Magnética , Polimorfismo Genético , Polimorfismo de Nucleotídeo Único , Córtex Pré-Frontal , Transtornos de Estresse Pós-Traumáticos
10.
Psychiatry Investigation ; : 56-61, 2013.
Artigo em Inglês | WPRIM | ID: wpr-17597

RESUMO

OBJECTIVE: Both clinical and biological factors influence the course of depressive disorders. This study tested for associations between the brain-derived neurotrophic factor (BDNF) gene at the Val66Met locus and the course of major depressive disorder (MDD). METHODS: Three hundred ten Korean subjects (209 patients, 101 controls) were genotyped for rs6265 at nucleotide 196 (G/A), which produces an amino acid substitution at codon 66 (Val66Met) of the gene for BDNF. Course of illness was evaluated both by chronicity of current episode (episode duration >24 months) and by the lifetime history of recurrences. RESULTS: Patients with the Met/Met BDNF genotype had a significantly higher rate of chronic depression than all others. There was a significant dose effect of the Met allele on chronicity. Compared with the Val/Val genotype, the relative risk of chronicity was 1.67 for the Val/Met genotype, and 2.58 for the Met/Met genotype. Lifetime history of recurrent episodes was not related to BDNF genotypes but was significantly associated with younger age of onset and with a history of depression in first degree relatives. CONCLUSION: BDNF genotyping may be informative for anticipating chronicity in major depression.


Assuntos
Humanos , Idade de Início , Alelos , Substituição de Aminoácidos , Fatores Biológicos , Fator Neurotrófico Derivado do Encéfalo , Códon , Depressão , Transtorno Depressivo , Transtorno Depressivo Maior , Genótipo
11.
Journal of Korean Geriatric Psychiatry ; : 34-39, 2008.
Artigo em Coreano | WPRIM | ID: wpr-66875

RESUMO

OBJECTIVES: Recent studies suggest that brain-derived neurotrophic factor (BDNF) may play a critical role in both mechanism of antidepressant action and the pathophysiology of major depressive disorder (MDD). The aim of this study is to evaluate whether the BDNF-gene Val66Met polymorphism is associated with susceptibility of MDD, and antidepressant response in a Korean population. METHODS: To explain genetic susceptibility of MDD, we genotyped the BDNF-gene Val66Met polymorphism in 137 patients with MDD and 91 age- and sex-similar control subjects. we also examined the association of the BDNF-gene Val66Met polymorphism and therapeutic response in 137 MDD patients who received a 6-week Selective Serotonin Reuptake Inhibitor (SSRI) treatment. RESULTS: There were no significant differences in the genotype or allele frequency of the BDNF polymorphism, between the MDD and control subjects. Furthermore, no significant differences were noted in the three-genotype groups (Val/Val, Val/Met, Met/Met) between responders and non-responders. However, heterozygous patients (Val/Met) in comparison to homozygous analogs (Val/Val or Met/Met) in BDNF polymorphism tended to have more improved 6-week antidepressant response (p=0.053). In addition, higher total HAM-D-score percentage change after 6 weeks of antidepressant medication was demonstrated for the heterozygote patients in comparison to homozygous analogs (p=0.006). CONCLUSION: This finding suggests the BDNF polymorphism is associated with improved therapeutic SSRI response for patients bearing the BDNF Val/Met heterozygote in comparison to the homozygous analogs.


Assuntos
Humanos , Fator Neurotrófico Derivado do Encéfalo , Transtorno Depressivo Maior , Frequência do Gene , Predisposição Genética para Doença , Genótipo , Heterozigoto , Polimorfismo Genético , Serotonina , Ursidae
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA